Introduction
Numerous studies proved that the clinical outcome in the invasive breast carcinoma is significantly associated with its genetic subtype [1] [2] [3] [4] [5] [6] . Recently, the distinction of the specific molecular subtypes was also applied for in situ breast carcinomas [7] [8] [9] . The criteria for molecular classification remained the same as in case of invasive carcinomas. The markers used for defining molecular subtypes were the following: estrogen receptor (ER), human epidermal growth factor receptor type 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK5/6). This classic panel of molecular profiling markers was proposed by Nielsen et al. for invasive breast carcinomas 10 and later extended to classify carcinomas in situ. Although numerous studies were performed on the molecular subtypes of breast carcinoma, mammary Paget's cells are still a set of specific neoplastic cells that remains to be defined on the molecular grounds. The association between the lesions located in the nipple and the underlying breast carcinoma was described originally in 1874 by Sir James Paget 11 . Nowadays, the coexistence of parenchymal breast carcinoma is observed in 67%-100% of patients with Paget's disease of the nipple [12] [13] [14] . On the other hand, Paget's disease of the nipple is diagnosed in 0.5%-5% of all breast carcinoma patients [15] [16] [17] [18] [19] . The expanding oozing and eczematous appearance of the nipple is the most common clinical presentation of the Paget's disease of nipple. The diagnosis of the disease is based on the identification of intraepidermal large, atypical cells with pale cytoplasm and these cells are referred to as 'the Paget's cells' 20 . They are dispersed among the basal layer but may be also identified in the upper portions of the epidermis ('pagetoid spread'). Their origin is not clear. There are two hypotheses explaining their derivation. 'Epidermotropic theory' suggests that they derive from the underlying breast carcinoma as they migrate along the mammary duct system into the nipple. The other hypothesis, 'intraepidermal transformation theory', states that the Paget's cells develop in the epidermis as a result of the morphological (and biological) change of the epidermal keratinocytes [21] [22] [23] . The more popular, epidermotropic theory is supported by the observation of frequent coexistence of the invasive breast carcinoma with Paget's disease of the nipple 13, 24 . On the other hand, the minority of cases without diagnosable breast cancer containing associated invasive carcinoma. In these 'good quality' archival tissues complete immunophenotyping was performed. All these tissue blocks were derived from 57 patients.
Material and methods

Study design
These patients composed the study group.
Characteristics of study group
Deleted: Finally, 57 cases were included into the study group. Grade 3 was diagnosed in 16 cases; grade 2 was found in the remaining 5 cases.
Immunohistochemical staining
The sections stained with haematoxylin and eosin (H&E) were used to identify Fisher exact test with Freeman-Halton correction. P-value <0.05 was considered significant.
Results
Immunohistochemical stainings
Due to some loss of studied material during preparation Table 2 . 
Classification of Paget's cells and underlying carcinomas to specific molecular subtypes
Paget's cells
Comparison of distributions of molecular subtypes
The distributions of molecular subtypes in Paget's cells, in the underlying in situ and invasive breast carcinomas were similar (Fisher exact test with Freeman-Halton correction,
P=0.93).
Discussion
Paget's cells of the nipple presented predominantly with HER2 molecular subtype.
This subtype was identified in 86% of cases. However, the molecular profiles of studied cases were not homogenous in this respect. Luminal B (in 12% of cases) and luminal A (in 2% of cases) were also identified, albeit rarely, and neither basal-like molecular subtype nor unclassified cases were diagnosed. Interestingly, the distribution of molecular subtypes in 28.6% of studied cases 30, 32, 33 , and the expression of PR was described in 0-28.6% 32, 33 . We have identified the frequency of these receptors in 14% and 7% of cases of Paget disease, respectively. EGFR expression in Paget's cells was studied by Schelfhout et al. 31 and revealed in 13% of cases. This generally remains in the similar rank in our study (9% [34] [35] [36] [37] [38] . During the construction of the TMAs we took four cores from each selected portion of the tumour tissue and used 0,6 mm punches. According to several authors three cores per sample are fully representative of the whole tumour 34, 37, 39, 40 . Taking into account random localization and scarcity of Paget's cells in the epidermis we decided to perform four cores from each case. Likewise, we considered using larger size of punches (1.5 mm), but as described by Kallioniemi et al. multiple 0.6 mm cores are sufficient to acquire an adequate amount of tissue 41 . Before we started the study we were fully aware of difficulties which could be encountered during construction of TMA in such a peculiar material as that occurring in Paget's disease. Indeed, precise sampling of clusters of Paget's cells from nipple epidermis was a difficult part of our study. However, despite difficulties, we were able to study expression of all the analysed proteins in 43 to 47 out of 49 initially sampled cases. Surprisingly, the major problems were encountered when foci of DCIS were sampled. It appeared that a substantial number of DCIS foci were too small to obtain the the criteria of positivity were less demanding, as any degree of immunoreactivity was regarded as positive in regard to basal cytokeratins (CK5/6 and CK17) and EGFR. These criteria were shared by other authors 7, 9, 10 . Although a single cell with cytoplasmic staining was sufficient for diagnosis of cytokeratine-positive case, we found only one such case in the whole series. We found only one CK5/6-positive case of DCIS. There was no CK17-positive cases. However, we are convinced about good quality of our IHC staining as CK5/6 ( Figure   2 ) and CK17 were demonstrated in the cells of the nipple epidermis.
In conclusion, our study revealed that HER2-positive molecular subtype was a 
